

15th EudraVigilance Information Day

Event ID 14501
12 March 2014
European Medicines Agency, London, United Kingdom



Programme Committee

Paolo Alcini

Head Data Collection and Management, EMA, EU

Peter Arlett

Head of Pharmacovigilance Department, EMA, EU

Sabine Brosch

Monitoring and Incident Management,
Pharmacovigilance, European Medicines Agency
(EMA), EU

Gaby Danan

Pharmacovigilance Expert, France

Anja van Haren

EudraVigilance Coordinator, Medicines Evaluation
Board (MEB), The Netherlands

Faculty

Laurent Auclert

Qualified Person Responsible for Pharmacovigilance
(QPPV), Sanofi-Aventis R&D, FR

Gianmario Candore

Scientific Administrator, European Medicines
Agency (EMA), EU

Georgy Genov

Head, Signal Management, European Medicines
Agency (EMA), EU

Mick Foy

Vigilance Intelligence and Research Group, Group
Manager, MHRA, UK

Nick Halsey

Scientific Administrator, European Medicines
Agency (EMA), EU

Steven Le Meur

Scientific Administrator, European Medicines
Agency (EMA), EU

Tom Paternoster

Scientific Administrator, European Medicines
Agency (EMA), EU

Kelly Plueschke

Scientific Administrator, European Medicines
Agency (EMA), EU

Izabela Skibicka

Scientific Administrator, European Medicines
Agency (EMA), EU

Sabine Straus

Head of Pharmacovigilance, Medicines Evaluation
Board (MEB), NL

Need for this EudraVigilance Information Day

EudraVigilance Information Days provide a forum to update stakeholders about the achievements and latest developments with regard to EudraVigilance in the broader context of implementation of the pharmacovigilance legislation.

A dedicated session on EudraVigilance will provide a summary of the EudraVigilance functionalities, which are, according to Article 24 of Regulation 726/2004, subject to an independent audit. A progress update on the preparation for literature monitoring services by the Agency as well as on the finalisation of the EU ICSR Implementation Guide will be also provided.

This Information Day will also provide an insight into the three year EU-wide pharmacovigilance project coordinated by MHRA and referenced as "Strengthening Collaboration for Operating Pharmacovigilance in Europe" (SCOPE). This Joint Action aims to further strengthen pharmacovigilance with main focus on operation at Member States level.

Other topics addressed will include the communication and follow up of safety signals, frequently raised implementation questions related to GVP module VI and commonly encountered data quality issues in relation to ICSR reporting.

Key Topics

- Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE)
- EudraVigilance functionalities to be audited
- Monitoring of medical literature by the Agency and the entry of relevant information into EudraVigilance
- EudraVigilance data quality
- Experience following publication of PRAC recommendations based on safety signals
- GVP Module VI – questions and answers session
- Notification process on withdrawn products

Who Will Attend

This programme will benefit Qualified Persons Responsible for Pharmacovigilance (QPPVs) and individuals involved in:

- Pharmacovigilance
- Clinical Development
- Information Management
- Safety databases

Details of the Information Day

Location: European Medicines Agency
7 Westferry Circus
Canary Wharf
London E14 4HB, UK

Capacity: The event is limited to 120 participants

EudraVigilance



08:15 Registration

08:45 Welcome Note

Peter Arlett, Head, Pharmacovigilance and Risk Management, EMA, EU

Session chairs for the 15th EudraVigilance Information Day:

Anja van Haren and Sabine Brosch

09:00 Session 1

EUDRAVIGILANCE

This session gives insight into the EudraVigilance functionalities to be audited in accordance with Article 24 of Regulation (EC) 726/2004 and a status update on the preparations for the literature monitoring activities by the Agency in line with Article 27 of the Regulation.

EudraVigilance functionalities to be audited

Sabine Brosch and Nick Halsey, EMA, EU

Status update on the monitoring of medical literature and the entry of relevant information into EudraVigilance

Sabine Brosch, EMA, EU and Steven Le Meur, EMA, EU

09:45 Session 2

EU ICSR IMPLEMENTATION GUIDE UPDATE

The audience will be updated on the finalisation of the EU ICSR Implementation Guide, which is key to the preparation for the implementation of the ISO ICSR standard.

ICH E2B (R3) – EU ICSR Implementation Guide

Nick Halsey, EMA, EU

10:15 COFFEE BREAK

10:45 Session 2 (continued)

EUDRAVIGILANCE

Aspects related to expedited compliance monitoring and frequently encountered data quality issues related to Individual Case Safety Reports (ICSRs) submitted to EudraVigilance will be addressed.

The duplicate detection algorithm in EudraVigilance

Gianmario Candore, EMA, EU

Data quality management – expedited reporting compliance and frequently encountered data quality issues in ICSRs

Tom Paternoster, EMA, EU

12:00 SANDWICH LUNCH

13:00 Session 3

SIGNAL MANAGEMENT

As of September 2013, PRAC recommendations on signals are published on a monthly basis. This session provides an overview of signals related activities from a regulators' and pharmaceutical industry's perspective.

Management of signals from an EU regulator's perspective

Sabine Straus, MEB, NL

Management of signals from an EMA perspective

Georgy Genov, EMA, EU

Experience with PRAC signals (follow-up and communication) from an industry perspective

Laurent Auclert, QPPV Sanofi, Chairman EFPIA PV Committee, France

14:30 COFFEE BREAK

15:00 Session 4

PHARMACOVIGILANCE LEGISLATION IMPLEMENTATION

GVP Module VI – questions and answers

Izabela Skibicka, EMA, EU and Gaby Danan, France

Notification process of withdrawn products

Kelly Plueschke, EMA, EU

16:15 Session 5

SCOPE

This session will provide an overview of the key objective of SCOPE aiming to enable national Competent Authorities in Member States to further progress from implementation of the pharmacovigilance legislation to the operation of the legal requirements to the highest possible standards against agreed benchmarks and best practices.

Mick Foy, MHRA, UK

17:00 END OF INFORMATION DAY

About DIA

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China.

Unless otherwise disclosed, DIA Europe acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA Europe. Speakers and agenda are subject to change without notice. Recording during DIA Europe sessions is strictly prohibited without prior written consent from DIA Europe.

HOTEL INFORMATION

HOTEL INFORMATION

Recommended Hotel:

Hilton London Docklands Riverside

265 Rotherhithe Street, London, SE16 5HW, UK

Telephone: +44 20 7231 1001

Email: reservations.docklands@hilton.com

DIA has blocked a limited number of rooms at the rate of GBP 139.00 single and GBP 149.00 double room/night including breakfast and VAT. To make your booking please visit the DIA event website.

The hotel is situated opposite of Canary Wharf, conveniently connected by a shuttle boat. The landing stage is in walking distance to the European Medicines Agency (2 min). The ferry ticket is included in the room rate. Please make sure you receive it when checking in.

For further information, please go to http://www1.hilton.com/en_US/hi/hotel/LONNDHI-Hilton-London-Docklands-hotel/index.do

DIA 2013 Training Courses in Safety and Pharmacovigilance

■ Benefit/Risk Management

19-20 May 2014 | Prague, Czech Republic | ID 14533
October 2014 | Location to be confirmed | ID 14547

■ Medical Approach in Diagnosis and Management of ADRs

22-23 September 2014 | Paris, France |

■ Diagnosis and Management of Drug-Induced Liver Injury (DILI)

23-24 September 2014 | Paris, France | ID 14544

■ How to Prepare for Pharmacovigilance Audits and Inspections

November 2014 | Location to be confirmed | ID 14550

■ ICH Endorsed Pharmacovigilance

21 October 2014 | Dakar, Senegal | ID 14559
November 2014 | Algiers, Algeria | ID 14560

■ Medical Approach in Diagnosis and Management of ADRs

22-23 September 2014 | Paris, France

■ Pre-Marketing Clinical Safety

16-17 June 2014 | Location to be confirmed | ID 14539

■ Post-Authorisation Safety Studies (PASS) *new offering!*

18-19 June 2014 | Location to be confirmed | ID 14535

■ Signal Management in Pharmacovigilance

21-22 May 2014 | Prague, Czech Republic | ID 14534
November 2014 | Location to be confirmed | ID 14549

European Medicines Agency Information Days and Courses

■ Excellence in Pharmacovigilance: Clinical trials and post-marketing

17-21 February 2014 | London, United Kingdom | ID 14500
13-17 October 2014 | London, United Kingdom | ID 14548

■ EnCePP Information Day

6 June 2014 | London, United Kingdom | ID 14503

■ EudraVigilance Information Day

12 March 2014 | London, United Kingdom | ID 14501

■ ICSR Information Day

13 May 2014 | London, United Kingdom | ID 14502

■ MedDRA Information Day

November 2014 | London, United Kingdom

■ PSUR Information Day

Date to be confirmed | London, United Kingdom

EudraVigilance courses:

- EudraVigilance – Electronic reporting of ICSRs in the EEA
- eXtended EudraVigilance Medicinal Product Dictionary
- Introduction to Pharmacovigilance and Rules for Expedited Reporting of Individual Case Safety Reports (ICSRs) in Europe

Courses throughout the year | European Medicines Agency, London, United Kingdom and selected European cities.

For information on EudraVigilance courses, please visit www.diahome.org > Meetings & Training > About Meetings & Training > In-Person Instruction > EudraVigilance > EudraVigilance Courses.

Network with Professional Colleagues Anywhere Anytime!

DIA Connex You
DIA's new members-only social networking-style website is a vital resource for professionals like you looking to connect with others in your field and improve your job performance.

Thousands of your colleagues will be part of DIA Connex, so don't get left behind.

How Can DIA Connex Help You?

- Get answers to on-the-job questions
- Access shared resources such as white papers and articles
- Network with thousands of your colleagues worldwide

Get connected at www.diahome.org/DIAconnex

DIA CONNEX
professional networking

www.diahome.org

REGISTRATION FORM

15th EudraVigilance Information Day

12 March 2014 | European Medicines Agency, London, United Kingdom



ID #14501

FAX YOUR COMPLETED REGISTRATION FORM TO: +41 61 225 51 52 or email to: diaeuropa@diaeuropa.org

FEES

Standard fee	€ 365.00	<input type="checkbox"/>
Reduced fee for Academia/Non-profit (Full-time)	€ 180.00	<input type="checkbox"/>
Reduced fee for Government	€ 180.00	<input type="checkbox"/>

The registration fee includes meeting material, sandwich lunch and refreshments.

Payment is due 30 days after registration and must be paid in full by commencement of the event.

TOTAL AMOUNT DUE: _____

ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

Prof Dr Ms Mr

Last Name

First Name

Company

Job Title

Address

Postal Code City

Country

Telephone

Fax

Email*

*(Required for confirmation)

DIA reserves the right to include your name and affiliation on the attendee list.

PAYMENT METHODS

Credit cards: Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

Please charge my VISA MC AMEX

Card N°

Exp. Date /

Cardholder's Name

Bank transfers: When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Event ID #14501 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA Europe.**

By signing below, I confirm that I agree with DIA Europe's Terms and Conditions of booking. These are available from the office or on <http://www.diahome.org/EUTerms>

Date

Signature

Cancellation Policy

All cancellations must be made in writing and be received at the DIA Europe office five working days prior to the event start date. Cancellations are subject to an administrative fee:

- Industry € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) € 100.00

If you do not cancel five working days prior to the event start date and do not attend, you will be responsible for the full registration fee. DIA Europe reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA Europe is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA Europe office of any such substitutions as soon as possible.

Photography Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA Europe in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.